InquirerMan arrested for illegal possession of loaded revolver in PalawanThe Jerusalem PostSmiles, scrunched brows: Guatemala shows off rare life-sized Maya stucco heads from El Mirador3DNewsVK Play Cloud запустил консольный тариф с бесплатным доступом к GTA VI, но есть нюансNOS EconomieAI-bedrijf Anthropic daalt hard op dag na historische beursgangZDF heuteAktuelle Pressemitteilungen des ZDFNOS SportOndanks hamstringklachten rekent Alcaraz snel af met Cobolli op ATP FInalsABC NewsIran live updates: Republicans block war powers resolutionkickerMit Maza gegen Paderborn: Comeback-Quintett sorgt für HärtefälleThe South AfricanWeather: Showers and thundershowers set to sweep across parts of SAComplete SportsArravo Team-2 wins FirstBank Corporate Golf Challenge for CharityWirtualna Polska"Bezwarunkowo potępiam". Burnham o naruszeniu polskiej przestrzeni powietrznejInteriaNowe informacje po naruszeniu. Wojewoda podkarpacka podpisała wniosek
The Daily Newsstand · Free, Always
Friday, November 20, 2026

India develops first indigenous H5N1 bird flu vaccine, priced at ₹1-2 per dose

Translate

India launched its first indigenous H5N1 bird flu vaccine priced at ₹1-2 per dose. The government says the vaccine will help limit poultry losses from recurring outbreaks and improve disease preparedness.

The government anticipates that the low-cost vaccine will improve access for small-scale farmers and enhance the country's preparedness for future avian flu outbreaks.
The government anticipates that the low-cost vaccine will improve access for small-scale farmers and enhance the country's preparedness for future avian flu outbreaks.(AP)

The government rolled out its first indigenous vaccine against the H5N1 strain of bird flu. Bird flu has been a major problem for the sector over the last 20 years, with hundreds of outbreaks and huge losses to farmers.

Developed by the ICAR-National Institute of High Security Animal Diseases (Nihsad) in Bhopal, the vaccine will be priced at ₹1-2 per dose. Agriculture minister Shivraj Singh Chouhan said it is designed to help contain outbreaks and to improve disease prevention in the sector as a whole.

The country has had over 500 cases of avian flu since 2006, resulting in the death or culling of millions of birds. It's still a concern as it can also infect mammals and, rarely, humans.

The government anticipates that the low-cost vaccine will improve access for small-scale farmers and enhance the country's preparedness for future avian flu outbreaks.

The first outbreak was in Navapur, Maharashtra, in 2006, resulting in the deaths of around 10 lakh chickens. To contain the infection, lakhs of additional birds had to be culled and buried. Subsequently, around 9 lakh chickens died in 2021, while another 2 lakh died this year, Chouhan said.

The affordable vaccine is expected to make preventive vaccination accessible to small poultry farmers, helping protect poultry stocks and livelihoods.

According to the Agricultural and Processed Food Products Export Development Authority (Apeda), India ranks second globally in egg production with 149.11 billion eggs in 2024–25, and poultry exports reached 2.46 million tonnes valued at $317.79 million in FY2025–26.

At the event in Bhopal, Chouhan also announced the establishment of a state-of-the-art animal disease research laboratory in the city at an estimated cost of ₹300 crore, strengthening India's research and diagnostic infrastructure.

Highlighting the economic burden of animal diseases, the minister said livestock and poultry are important sources of supplementary income for rural households. He cited annual losses of ₹22,000 crore from foot-and-mouth disease, ₹20,000 crore from lumpy skin disease, ₹9,212 crore from brucellosis and ₹4,683 crore from peste des petits ruminants. Together, these diseases account for an estimated annual economic burden of around ₹56,000 crore.

The government has administered 147.16 crore free vaccine doses against foot-and-mouth disease under the National Animal Disease Control Programme, while scientists have also developed indigenous vaccines against lumpy skin disease, classical swine fever and African swine fever.

The latest H5N1 vaccine adds to Nihsad’s portfolio of indigenous animal vaccines and is expected to strengthen India's preparedness against highly pathogenic avian influenza.

About the Author

Vijay C. Roy is a journalist with over 21 years of experience covering various news beats across different organisations such as Business Standard and The Tribune. In the past, he has covered beats such as finance, auto, MSME, commodities, FMCG, pharmaceutical, agriculture, IT/ITES, infrastructure and start-ups. He joined Mint in February 2025, and covers agriculture, food processing, fertilizers, environment and climate change, bringing over two decades of experience reporting on farm policy, food inflation, crop trade, and rural livelihoods.<br><br>Vijay’s areas of reporting include food security and climate change policies, focusing on their impact on different stakeholders and their implications. His expertise lies in simplifying complex agri-economic issues such as edible oil import dependence, cotton and wheat trends, fertiliser subsidies, and climate-related risks. He has covered key developments including global supply disruptions and evolving trade policies, offering both macroeconomic perspective and field-level context. Known for his credible and balanced reporting, he follows a rigorous, fact-based approach that prioritises accuracy and context. He is driven by a commitment to public interest, aiming to make critical agricultural and economic issues accessible while contributing to informed policy and industry discussions.

View the original on Mint →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.